Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...
More adverse events of grade 3 or higher reported for participants receiving pembrolizumab-belzutifan than pembrolizumab-placebo ...
In this study, the researchers examined the risk of multiple primary cancers in male WTC first responders in comparison to the general population.
Researchers studied the relationship between dermatologist density and the proportion of late-stage melanoma diagnoses.
The 4-year overall survival rates were 77.0% in the IACT arm and 76.4% in the olaparib arm. Outcomes for stage III HER2-negative breast cancer with homologous recombination deficiency (HRD) are not ...
At a median follow-up of 6.8 years, the 10-year PFS rate was 78.7%. Patients with platinum-sensitive recurrent ovarian cancer who remain progression-free for at least 5years on maintenance PARP ...
Higher transplant rates and post-transplant survival favored combination therapy despite neutral overall survival. Adding venetoclax to hypomethylating agents (HMA) improved response quality without ...
(HealthDay News) — Artificial intelligence-based risk scores from screening mammograms increase over time among women who develop cancer, and remain stable among women who remain cancer-free, ...
Each additional hour per day of prolonged sedentary behavior is associated with a higher hazard of cancer death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results